Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.38 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.38 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.38 |
| ▸ | CCKAR | P32238 | 1/20 | 0.38 |
| ▸ | CCKBR | P32239 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 2/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.37 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20345224 | 1.00 | AKT1 (0.45) | AKT1ALDH1A1SMN1; SMN2CHRNB2CHRNB4 | |
| SCHEMBL25877172 | 0.97 | AKT1 (0.43) | AKT1ALDH1A1SMN1; SMN2CCKARCCKBR | |
| SCHEMBL26170798 | 0.95 | OPRD1 (0.43) | AKT1OPRD1OPRM1OPRK1PSMB5 | |
| SCHEMBL25877099 | 0.94 | AKT1 (0.43) | AKT1ALDH1A1SMN1; SMN2OPRD1OPRM1 | |
| SCHEMBL28385636 | 0.93 | AKT1 (0.46) | AKT1ALDH1A1SMN1; SMN2OPRD1OPRM1 | |
| SCHEMBL22768342 | 0.93 | AKT1 (0.46) | AKT1ALDH1A1SMN1; SMN2OPRD1OPRM1 | |
| SCHEMBL17003582 | 0.93 | AKT1 (0.46) | AKT1ALDH1A1SMN1; SMN2OPRD1OPRM1 | |
| SCHEMBL28385639 | 0.93 | AKT1 (0.46) | AKT1ALDH1A1SMN1; SMN2OPRD1OPRM1 | |
| SCHEMBL18224261 | 0.93 | AKT1 (0.46) | AKT1ALDH1A1SMN1; SMN2OPRD1OPRM1 | |
| SCHEMBL23790034 | 0.92 | AKT1 (0.40) | AKT1ALDH1A1SMN1; SMN2CHRNB2CHRNB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3958977-B1 | CAMPTOTHECIN DERIVATIVES | IMMUNOGEN INC (US) | 2023-09-13 | — | — | EP | disclosed |
| US-20220133711-A1 | CAMPTOTHECIN DERIVATIVES | IMMUNOGEN, INC. | 2022-05-05 | — | — | US | disclosed |
| US-20210077482-A1 | CAMPTOTHECIN DERIVATIVES | IMMUNOGEN, INC. | 2021-03-18 | — | — | US | disclosed |
| EP-2907824-B1 | ANTIBODY-DRUG CONJUGATE | DAIICHI SANKYO CO LTD (JP) | 2018-04-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210077482-A1 | CAMPTOTHECIN DERIVATIVES | TOP2A, TOP2B, PCNA | AKT1 117/4885ALDH1A1 1182/4885SMN1; SMN2 4361/4885 |
| US-20220133711-A1 | CAMPTOTHECIN DERIVATIVES | TOP2A, TOP2B, PCNA | AKT1 117/4885ALDH1A1 1182/4885SMN1; SMN2 4361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.